04:46 PM EDT, 09/26/2024 (MT Newswires) -- Qiagen ( QGEN ) said Thursday its QIAstat-Dx systems for syndromic testing and associated tests have been granted CE-marking by the European Union's new In-Vitro Diagnostic Medical Devices Regulation.

The QIAstat-Dx system uses PCR technology to detect several pathogens simultaneously, the company said.

The standard QIAstat-Dx model combines up to four analytical modules into a unified system, while the advanced Rise model offers extensive testing capabilities for up to 160 tests daily with eight analytical modules, according to Qiagen ( QGEN ).